PDCD1 and neoplasm: It also up‐regulated interferon‐stimulated genes—including MHC class I and PD‐L1—thereby priming the tumor for checkpoint blockade; when combined with anti‐PD‐1 therapy, this regimen reversed adaptive immune resistance and produced superior tumor control [19].